Using genetic characterization data from CCLE69, we did not find any lesion which segregated FASTS cells from other CD33 + AML cells (Fig. 6a), so no mutation is nominated to drive a FASTS phenotype in vivo. Here, CD33 is linked to acute myeloid leukemia.